Lassa fever laboratory findings

Lassa fever Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Lassa fever from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lassa fever laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lassa fever laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lassa fever laboratory findings
CDC on Lassa fever laboratory findings
Lassa fever laboratory findings in the news
Blogs on Lassa fever laboratory findings
Directions to Hospitals Treating Lassa fever
Risk calculators and risk factors for Lassa fever laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ammu Susheela, M.D. [2]

Synonyms and keywords: Lassa hemorrhagic fever; LHF

Overview

There is a range of laboratory investigations that are performed to diagnose the disease and assess its course and complications. In West Africa, where Lassa is most prevalent, it is difficult for doctors to diagnose due to the absence of proper equipment to perform tests. Research has been done in the last few years, by a team of specialists, in order to diagnose the Lassa fever on a molecular level. Potentially infectious diagnostic specimens are routinely handled and tested in U.S. laboratories in a safe manner, by closely following the standard safety precautions.

Serology

• The mainstay of diagnosis of Lassa fever is detection of either Lassa antibodies in patient sera.
• Patients with acute Lassa fever infection typically have high concentration of Lassa IgG antibodies, whereas patients already infected in the past have high IgM Lassa antibodies.

Other Laboratory tests

• The following table summarizes the lab tests and laboratory findings associated with Lassa fever:

Laboratory findings

Lab tests	Laboratory findings
Complete Blood Count (CBC)	Lymphocytopenia, thrombocytopenia
Liver function tests	Elevated aspartate aminotransferase (AST)
Urinalysis	Proteinuria
Chest X-rays	Chest X-rays typically demonstrates basilar pneumonitis and pleural effusions.
Viral culture	The virus often delays the diagnosis and may be cultured in 7 to 10 days
Viral isolation	Viral isolation is the most sensitive technique, but is infrequently used. The virus may be observed under electron microscopy. Obtain samples from blood, urine, pleural effusion, or throat swab of living patients or from tissue samples (either liver, kidney, spleen, or heart) of dead patients.

Handling of Laboratory Samples

Guidance for Collection, Transport, and Submission of Specimens for Virus Testing

• Lassa virus is graded as biosafety level 4 according to The Centers for Disease Control and Prevention (CDC) classification.
• Ideally, specimens should be taken when a symptomatic patient reports to a healthcare facility and is suspected of having an exposure to the disease. However, if the onset of symptoms is <3 days, a later specimen may be needed to completely rule-out virus, if the first specimen tests negative.
• A minimum volume of 4 mL of whole blood preserved with EDTA is preferred, but whole blood preserved with either sodium polyanethol sulfonate, citrate, or clot activator may be submitted for testing. Heparin tubes are not recommended.
• Specimens should be shipped at 2-8°C or frozen on cold-packs, but not in glass containers.

Transporting Specimens Within the Hospital/Institution

• Specimens should be placed in a durable, leak-proof secondary container for transport within a facility. To reduce the risk of breakage or leaks, do not use any pneumatic tube system for transporting suspected virus specimen.
• Packing and shipping infectious substances must be performed by people trained and certified in compliance with DOT or International Air Transport Association requirements.